Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.68 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 2/20 | 0.62 |
| ▸ | NPC1 | O15118 | 8/20 | 0.60 |
| ▸ | RAB9A | P51151 | 7/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.60 |
| ▸ | HPGD | P15428 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | CES2 | O00748 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7503385 | 0.82 | KDM4E (0.70) | KDM4EHDAC1TSHRNPC1RAB9A | |
| SCHEMBL2199589 | 0.81 | GAA (0.69) | KDM4EHDAC1TSHRNPC1RAB9A | |
| SCHEMBL16181983 | 0.81 | KDM4E (0.68) | KDM4EHDAC1TSHRNPC1RAB9A | |
| SCHEMBL1520699 | 0.80 | KDM4E (0.62) | KDM4EHDAC1TSHRNPC1RAB9A | |
| SCHEMBL4578943 | 0.79 | KDM4E (0.77) | KDM4EHDAC1TSHRNPC1RAB9A | |
| SCHEMBL4578939 | 0.79 | KDM4E (0.77) | KDM4EHDAC1TSHRNPC1RAB9A | |
| SCHEMBL7394648 | 0.79 | KDM4E (0.66) | KDM4EHDAC1TSHRNPC1RAB9A | |
| SCHEMBL6127192 | 0.79 | KDM4E (0.89) | KDM4EHDAC1TSHRNPC1RAB9A | |
| SCHEMBL1222245 | 0.79 | KDM4E (0.66) | KDM4EHDAC1TSHRNPC1RAB9A | |
| SCHEMBL21479628 | 0.79 | KDM4E (0.60) | KDM4EHDAC1TSHRNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0092830-A2 | Cephalosporin derivatives, process for their preparation, pharmaceutical compositions containing them and their application | CIBA-GEIGY AG (CH) | 1983-11-02 | — | — | EP | claimed |
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-03-22 | — | — | US | disclosed |
| US-20120020920-A1 | 5-5-MEMBERED FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-01-26 | — | — | US | disclosed |
| US-7977331-B1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2011-07-12 | — | — | US | disclosed |
| EP-2206715-A1 | Fused heterotetracyclic compounds and use thereof as hcv polymerase inhibitor | Japan Tobacco, Inc. (JP) | 2010-07-14 | — | — | EP | disclosed |
| US-7659263-B2 | Thienopyrrole compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2010-02-09 | — | — | US | disclosed |
| US-20090036444-A1 | 5-5-Membered fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2009-02-05 | — | — | US | disclosed |
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2007-03-01 | — | — | US | disclosed |
| EP-1719773-A1 | FUSED HETEROTETRACYCLIC COMPOUNDS AND USE TEHREOF AS HCV POLYMERASE INHIBITOR | Japan Tobacco, Inc. (JP) | 2006-11-08 | — | — | EP | disclosed |
| EP-1688420-A1 | 5-5-MEMBERED FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2006-08-09 | — | — | EP | disclosed |
| US-5854407-A | 15-hydroxy 6,9-hemiacetal erythromycin compounds | TAKEDA CHEMICAL CORPORATION (JP) | 1998-12-29 | — | — | US | disclosed |
| EP-0561413-B1 | Erythromycin deriatives, preparation and use thereof | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1996-06-05 | — | — | EP | disclosed |
| US-5470961-A | 14 and/or 15-hydroxy 6,9 hemiacetal erythromycin derivatives | TAKEDA CHEMICAL IND., LTD. (JP) | 1995-11-28 | — | — | US | disclosed |
| EP-0561413-A1 | Erythromycin deriatives, preparation and use thereof | Takeda Chemical Industries, Ltd. (JP) | 1993-09-22 | — | — | EP | disclosed |
| US-5175150-A | Stimulating digective contraction | KITASATO, KENKYUSHO (JP) | 1992-12-29 | — | — | US | disclosed |
| US-5008249-A | Administering anhydroerythromycin derivative | KITASATO KENKYUSHO (JP) | 1991-04-16 | — | — | US | disclosed |
| US-4948782-A | A method of promoting the growth of domestic animals with erythromycin derivative containing composition | KITASATO KENKYUSHO (JP) | 1990-08-14 | — | — | US | disclosed |
| EP-0215355-A2 | Erythromycin derivative and process for preparing the same | KITASATO KENKYUSHO (JP) | 1987-03-25 | — | — | EP | disclosed |
| EP-0213617-A2 | Digestive tract contractile motion stimulant | KITASATO KENKYUSHO (JP) | 1987-03-11 | — | — | EP | disclosed |
| EP-0092830-A2 | Cephalosporin derivatives, process for their preparation, pharmaceutical compositions containing them and their application | CIBA-GEIGY AG (CH) | 1983-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | POLI, TERT, ZC3HAV1 | KDM4E 2725/4885HDAC1 182/4885TSHR 4089/4885 |
| US-20090036444-A1 | 5-5-Membered fused heterocyclic compound and use thereof as HCV polymerase inhibitor | GTF3C5, ZC3HAV1, POLI | KDM4E 1520/4885HDAC1 316/4885TSHR 4648/4885 |
| US-20120020920-A1 | 5-5-MEMBERED FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | GTF3C5, ZC3HAV1, POLI | KDM4E 1520/4885HDAC1 316/4885TSHR 4648/4885 |
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | POLI, TERT, ZC3HAV1 | KDM4E 2725/4885HDAC1 182/4885TSHR 4089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.